Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Safety and Efficacy Study of GRT6005 in Patients With Osteoarthritis (OA) Knee Pain

ClinicalTrials.gov ID: NCT01709214

Public ClinicalTrials.gov record NCT01709214. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 4, 2026, 11:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo- and Active Controlled Study to Evaluate the Safety and Efficacy of GRT6005 in Patients With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the safety and efficacy of GRT6005 compared to placebo in patients with moderate to severe chronic pain due to osteoarthritis (OA) of the knee. This study includes a maximum 21 day Screening Period followed by a 15-week Double-blind Treatment Period and a 4-7 day Safety Follow-up period. Patients who are eligible for the Double-blind Treatment Period will be randomized to one of following treatment groups: GRT6005 high-dose range (400, 600 or 800 mcg), GRT6005 low-dose range (200, 300 or 400 mcg), oxycodone controlled release (CR) dose range (10, 20, 30, 40 or 50 mg) or placebo.

Study identification

NCT ID
NCT01709214
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Tris Pharma, Inc.
Industry
Enrollment
619 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 3, 2012
Primary completion
Mar 31, 2014
Completion
Apr 3, 2014
Last update posted
Jul 14, 2021

2012 – 2014

United States locations

U.S. sites
83
U.S. states
26
U.S. cities
77
Facility City State ZIP Site status
Site 051 Birmingham Alabama 35209
Site 022 Birmingham Alabama 35216
Site 031 Huntsville Alabama 35801
Site 005 Phoenix Arizona 85018
Site 018 Phoenix Arizona 85023
Site 070 Phoenix Arizona 85027
Site 028 Tucson Arizona 85712
Site 081 Chino California 91710
Site 030 El Cajon California 92020
Site 039 Fair Oaks California 95628
Site 061 Fresno California 93726
Site 084 North Hollywood California 91606
Site 080 Roseville California 95661
Site 004 Sacramento California 95821
Site 044 San Diego California 92117
Site 043 Tustin California 92780
Site 010 Walnut Creek California 94598
Site 027 Westlake Village California 91361
Site 011 Bradenton Florida 34209
Site 071 Clearwater Florida 33761
Site 090 Edgewater Florida 32132
Site 060 Jacksonville Florida 32256
Site 015 Jupiter Florida 33458
Site 013 Miami Florida 33144
Site 003 New Port Richey Florida 34652
Site 012 Ocala Florida 34474
Site 032 Orlando Florida 32806
Site 025 Ormond Beach Florida 32174
Site 058 Pembroke Pines Florida 33028
Site 091 Pinellas Park Florida 33781
Site 007 Sarasota Florida 34238
Site 052 Marietta Georgia 30066
Site 033 Perry Georgia 31069
Site 073 Stockbridge Georgia 30281
Site 086 Chicago Illinois 60612
Site 041 Indianapolis Indiana 46260
Site 085 Valparaiso Indiana 46383
Site 088 Towson Maryland 21204
Site 077 Wheaton Maryland 20902
Site 083 New Bedford Massachusetts 02740
Site 021 North Dartmouth Massachusetts 02747
Site 020 Worcester Massachusetts 01605
Site 016 Bingham Farms Michigan 48025
Site 042 Traverse City Michigan 49684
Site 023 St Louis Missouri 63141
Site 087 Grand Island Nebraska 68803
Site 074 Omaha Nebraska 68144
Site 024 Las Vegas Nevada 89130
Site 072 Las Vegas Nevada 89144
Site 009 Albuquerque New Mexico 87102
Site 068 Albany New York 12208
Site 017 Hartsdale New York 10530
Site 056 Greensboro North Carolina 27410
Site 006 High Point North Carolina 27262
Site 078 Wilmington North Carolina 28401
Site 079 Cincinnati Ohio 45219
Site 008 Cincinnati Ohio 45242
Site 069 Cleveland Ohio 44122
Site 001 Columbus Ohio 43213
Site 048 Toledo Ohio 43623
Site 075 Oklahoma City Oklahoma 73103
Site 029 Bend Oregon 97701
Site 067 Medford Oregon 97504
Site 035 Portland Oregon 97239
Site 045 Altoona Pennsylvania 16602
Site 002 Duncansville Pennsylvania 16635
Site 034 Anderson South Carolina 29621
Site 076 Charleston South Carolina 29407
Site 093 Bristol Tennessee 37620
Site 055 Austin Texas 78731
Site 049 Bryan Texas 77802
Site 038 Dallas Texas 75203
Site 089 San Antonio Texas 78209
Site 040 San Antonio Texas 78229
Site 082 Wichita Falls Texas 76309
Site 019 Draper Utah 84020
Site 064 Ogden Utah 84405
Site 059 Salt Lake City Utah 84106
Site 092 Norfolk Virginia 23507
Site 026 Virginia Beach Virginia 23454
Site 066 Bellevue Washington 98007
Site 057 Renton Washington 98057
Site 065 Seattle Washington 98122

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01709214, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 14, 2021 · Synced Sep 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01709214 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →